Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 15;20(3):256-261.
doi: 10.7861/clinmed.2020-0149. Print 2020 May 5.

Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic

Elizabeth Price  1 , Elizabeth MacPhie  2 , Lesley Kay  3 , Peter Lanyon  4 , Bridget Griffiths  5 , Christopher Holroyd  6 , Abhishek Abhishek  7 , Taryn Youngstein  8 , Kathryn Bailey  9 , Jacqui Clinch  10 , Muddassir Shaikh  11 , Ali Rivett  12
Affiliations

Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic

Elizabeth Price et al. Clin Med (Lond). .

Abstract

Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England.

Keywords: COVID-19; SARS-CoV-2; health economics; innovation; testing.

PubMed Disclaimer

References

    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020, in press (DOI: 10.1056/NEJMoa2002032). - PMC - PubMed
    1. Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020, in press: (DOI: annrheumdis-2020-217424). - PMC - PubMed
    1. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Medicine 2006;3:e343. - PMC - PubMed
    1. Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 2016;42:157–76. - PMC - PubMed
    1. Waki D, Nishimura K, Tokumasu H, et al. Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. Medicine 2020;99:e19173. - PMC - PubMed